Sangamo BioSciences Announces Presentation At The Lazard Capital
Markets Healthcare Conference
RICHMOND, Calif., Nov. 6, 2012 /PRNewswire/ -- Sangamo
BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO,
will provide an update on the progress of Sangamo's ZFP
Therapeutic® development programs and an overview of the
company's business strategy at 3:30 pm
ET on Tuesday, November 13,
2012, at the Lazard Capital Markets 9th Annual Healthcare
Conference which will be held in New York
City.
The presentation will be webcast live and may be accessed via a
link on the Sangamo BioSciences website in the Investor Relations
section http://investor.sangamo.com/index.cfm under Events and
Presentations. The presentation will be archived on the Sangamo
website for two weeks after the event.
About Sangamo
Sangamo BioSciences, Inc. is focused on
research and development of novel DNA-binding proteins for
therapeutic gene regulation and genome editing. The Company has
ongoing Phase 2 clinical trials to evaluate the safety and efficacy
of a novel ZFP Therapeutic® for the treatment of HIV/AIDS.
Sangamo's other therapeutic programs are focused on monogenic
diseases, including hemophilia, Huntington's disease and
hemoglobinopathies such as sickle cell anemia and beta-thalassemia.
Sangamo's core competencies enable the engineering of a class of
DNA-binding proteins known as zinc finger DNA-binding proteins
(ZFPs). Engineering of ZFPs that recognize a specific DNA
sequence enables the creation of sequence-specific ZFP Nucleases
(ZFNs) for gene modification and ZFP transcription factors (ZFP
TFs) that can control gene expression and, consequently, cell
function. Sangamo has entered into a strategic collaboration with
Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic
diseases and has established strategic partnerships with companies
in non-therapeutic applications of its technology including Dow
AgroSciences and Sigma-Aldrich Corporation. For more information
about Sangamo, visit the company's website at www.sangamo.com.
ZFP Therapeutic® is a registered trademark of Sangamo
BioSciences, Inc.
SOURCE Sangamo BioSciences, Inc.